NIH has released four new SBIR/STTR solicitations (first deadline for all solicitations is September 8, 2026): Parent SBIR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track SBIR awards Parent STTR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track STTR awards SBIR Phase IIB Strategic Breakthrough Award (Clinical Trial Optional) accepts Phase IIB Strategic Breakthrough SBIR awards (for Phase II awardees) SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Clinical Trial Optional) accepts CRP awards (for Phase II awardees) Updated summaries of the research interests, budget waiver topics, and award mechanisms supported by individual Institutes and Centers (ICs) are now housed on the Small Business Funding Considerations and Contacts webpage
Fast Response : Nasal delivery absorbs and clears quickly from the nasal cavity
The Problem With Normal: A negative TPO antibody test does not completely rule out Hashimotos approximately 5-10% of Hashimotos cases are seronegative (antibody-negative but positive on thyroid ultrasound, which shows the characteristic heterogeneous, coarsened thyroid texture of autoimmune inflammation)
The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications
Click to view the research paper
Supplement Facts / Label (Varies Product / Product): Warnings and Side Effects: For adults only